Study of ridostin Pro and Poly(I:C) as adjuvants that enhance the immunogenicity of an antitumor vaccine

Aim of the study: to compare the antitumor efficacy and immunogenicity of vaccines with the same antigens but different adjuvants: Ridostin Pro or Poly(I:C); to evaluate the effect of Ridostin Pro and Poly(I:C) on the cytokine profile of serum and the immunophenotype of mouse spleen cells. material and methods. To evaluate the antitumor efficacy of vaccines with different adjuvants, two transplantable tumor lines were used: melanoma B16-F10 and EG7-OVA lymphoma (expressing ovalbumin) for C57BL/6 mice. Against melanoma B16-F10, vaccination with the peptide TRP2 180-188 with the studied adjuvants was performed in a mixed (preventive/ therapeutic) and therapeutic regimens. Ovalbumin with adjuvants was vaccinated against EG7 lymphoma in a therapeutic mode. The immunogenicity of vaccines with different adjuvants in mice without tumors was evaluated by the ELISPOT method. In this case, the peptide TRP2 180-188 and the protein ovalbumin also served as antigens. The cytokine profile of blood serum and changes in the immunophenotype of mouse spleen cells after administration of Ridostin Pro or Poly(I:C) were studied using flow cytometry.